Setting new expectations in image-guided surgery
OTL was created with the belief that all physicians want to have confidence in their ability to see with clarity and treat with certainty. Our technology is intended to be incorporated in products to initially be applied in the diagnosis and staging of cancer, and if successful we believe it has the potential to ultimately improve the care of patients. Preclinical research suggests that OTL technology may also be applicable to other disease states including autoimmune diseases. Some of the other imaging agents on the market today have significant limitations because they may not be sufficiently sensitive or specific to the identification of diseased tissue, and they may result in false-positives within healthy cells. OTL38 is an illuminating and innovative proprietary compoud that has been developed to attach to diseased cells, allowing the clinician to distinguish those from healthy cells. Our compounds bind specifically to targeted disease tissue within minutes of injection. If successfully tested and approved, this will provide surgeons with a way to visually enhance the identification of disease. OTL38 has received orphan drug designation from the FDA.
For surgeons, new approaches
- Our tumor specific ligands are designed to enable the delivery of photosensitive agents specifically to cancer. The design could also lead to the activation of these agents to theoretically enable selective destruction of cancerous tissue that would otherwise be invisible to the surgeon.
For patients, more certainty at uncertain times
- Surgeons will tell you, that the most common refrain they hear from cancer patients pre-surgery is "just get it out." It is common for patients to be concerned about whether the surgeon was able to remove all the cancer. OTL strives to provide surgeons with the ability to see with more precision and therefore remove tissues that were previously hard to identify. Furthermore, if we can successfully target cancer cells, OTL could have the potential to determine the patient’s cancer stage through the visualization of diseased tissue. In the end, knowledge is power for surgeons, patients and their families.